vs
Side-by-side financial comparison of Ceribell, Inc. (CBLL) and Electromed, Inc. (ELMD). Click either name above to swap in a different company.
Ceribell, Inc. is the larger business by last-quarter revenue ($24.8M vs $18.9M, roughly 1.3× Electromed, Inc.). Electromed, Inc. runs the higher net margin — 14.6% vs -54.6%, a 69.2% gap on every dollar of revenue. Electromed, Inc. produced more free cash flow last quarter ($2.4M vs $-11.0M).
Ceribell, Inc. develops and commercializes innovative portable neurodiagnostic medical devices, focused on rapid non-invasive electroencephalogram (EEG) solutions for seizure detection. Its core products serve hospital emergency departments, intensive care units, and long-term care facilities, with primary markets across North America and ongoing global expansion efforts.
Electromed, Inc. is a specialized medical device firm developing, manufacturing, and distributing advanced respiratory care products. Its core offerings are high-frequency chest wall oscillation systems that clear airway secretions for patients with cystic fibrosis, COPD and other respiratory conditions, serving U.S. home care and clinical customers.
CBLL vs ELMD — Head-to-Head
Income Statement — Q4 2025 vs Q2 2026
| Metric | | |
|---|---|---|
| Revenue | $24.8M | $18.9M |
| Net Profit | $-13.5M | $2.8M |
| Gross Margin | 87.3% | 78.4% |
| Operating Margin | -58.9% | 19.2% |
| Net Margin | -54.6% | 14.6% |
| Revenue YoY | — | 16.3% |
| Net Profit YoY | — | 40.3% |
| EPS (diluted) | $-0.35 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $24.8M | $18.9M | ||
| Q3 25 | $22.6M | $16.9M | ||
| Q2 25 | $21.2M | $17.4M | ||
| Q1 25 | $20.5M | $15.7M | ||
| Q4 24 | — | $16.3M | ||
| Q3 24 | $17.2M | $14.7M | ||
| Q2 24 | — | $14.8M | ||
| Q1 24 | — | $13.9M |
| Q4 25 | $-13.5M | $2.8M | ||
| Q3 25 | $-13.5M | $2.1M | ||
| Q2 25 | $-13.6M | $2.2M | ||
| Q1 25 | $-12.8M | $1.9M | ||
| Q4 24 | — | $2.0M | ||
| Q3 24 | $-10.4M | $1.5M | ||
| Q2 24 | — | $1.8M | ||
| Q1 24 | — | $1.5M |
| Q4 25 | 87.3% | 78.4% | ||
| Q3 25 | 88.3% | 78.1% | ||
| Q2 25 | 88.1% | 78.3% | ||
| Q1 25 | 87.9% | 78.0% | ||
| Q4 24 | — | 77.7% | ||
| Q3 24 | 87.3% | 78.3% | ||
| Q2 24 | — | 76.2% | ||
| Q1 24 | — | 74.8% |
| Q4 25 | -58.9% | 19.2% | ||
| Q3 25 | -64.8% | 15.8% | ||
| Q2 25 | -70.5% | 17.5% | ||
| Q1 25 | -69.3% | 13.6% | ||
| Q4 24 | — | 15.6% | ||
| Q3 24 | -57.8% | 13.2% | ||
| Q2 24 | — | 15.7% | ||
| Q1 24 | — | 13.3% |
| Q4 25 | -54.6% | 14.6% | ||
| Q3 25 | -59.6% | 12.6% | ||
| Q2 25 | -64.4% | 12.7% | ||
| Q1 25 | -62.4% | 12.1% | ||
| Q4 24 | — | 12.1% | ||
| Q3 24 | -60.6% | 10.0% | ||
| Q2 24 | — | 12.3% | ||
| Q1 24 | — | 10.8% |
| Q4 25 | $-0.35 | $0.32 | ||
| Q3 25 | $-0.37 | $0.25 | ||
| Q2 25 | $-0.38 | $0.26 | ||
| Q1 25 | $-0.36 | $0.21 | ||
| Q4 24 | — | $0.22 | ||
| Q3 24 | $-1.85 | $0.16 | ||
| Q2 24 | — | $0.20 | ||
| Q1 24 | — | $0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $159.3M | $13.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $155.3M | $45.4M |
| Total Assets | $195.8M | $54.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $159.3M | $13.8M | ||
| Q3 25 | $168.5M | $14.1M | ||
| Q2 25 | $177.4M | $15.3M | ||
| Q1 25 | $182.7M | $15.2M | ||
| Q4 24 | — | $16.2M | ||
| Q3 24 | $14.1M | $13.9M | ||
| Q2 24 | — | $16.1M | ||
| Q1 24 | — | $11.7M |
| Q4 25 | $155.3M | $45.4M | ||
| Q3 25 | $164.1M | $44.7M | ||
| Q2 25 | $172.2M | $43.2M | ||
| Q1 25 | $180.9M | $43.9M | ||
| Q4 24 | — | $43.6M | ||
| Q3 24 | $-136.0M | $41.5M | ||
| Q2 24 | — | $44.5M | ||
| Q1 24 | — | $42.5M |
| Q4 25 | $195.8M | $54.9M | ||
| Q3 25 | $199.5M | $53.6M | ||
| Q2 25 | $207.7M | $53.8M | ||
| Q1 25 | $213.5M | $52.5M | ||
| Q4 24 | — | $52.3M | ||
| Q3 24 | $47.1M | $48.9M | ||
| Q2 24 | — | $52.2M | ||
| Q1 24 | — | $48.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-10.8M | $3.0M |
| Free Cash FlowOCF − Capex | $-11.0M | $2.4M |
| FCF MarginFCF / Revenue | -44.2% | 12.7% |
| Capex IntensityCapex / Revenue | 0.7% | 3.4% |
| Cash ConversionOCF / Net Profit | — | 1.10× |
| TTM Free Cash FlowTrailing 4 quarters | $-41.6M | $7.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-10.8M | $3.0M | ||
| Q3 25 | $-11.1M | $169.0K | ||
| Q2 25 | $-7.5M | $3.9M | ||
| Q1 25 | $-11.4M | $2.1M | ||
| Q4 24 | — | $3.2M | ||
| Q3 24 | — | $2.3M | ||
| Q2 24 | — | $4.5M | ||
| Q1 24 | — | $1.4M |
| Q4 25 | $-11.0M | $2.4M | ||
| Q3 25 | $-11.5M | $-83.0K | ||
| Q2 25 | $-7.6M | $3.7M | ||
| Q1 25 | $-11.6M | $1.9M | ||
| Q4 24 | — | $2.9M | ||
| Q3 24 | — | $2.3M | ||
| Q2 24 | — | $4.5M | ||
| Q1 24 | — | $1.3M |
| Q4 25 | -44.2% | 12.7% | ||
| Q3 25 | -50.8% | -0.5% | ||
| Q2 25 | -35.9% | 21.4% | ||
| Q1 25 | -56.4% | 12.2% | ||
| Q4 24 | — | 18.0% | ||
| Q3 24 | — | 15.5% | ||
| Q2 24 | — | 30.1% | ||
| Q1 24 | — | 9.1% |
| Q4 25 | 0.7% | 3.4% | ||
| Q3 25 | 1.6% | 1.5% | ||
| Q2 25 | 0.3% | 0.8% | ||
| Q1 25 | 0.7% | 1.0% | ||
| Q4 24 | — | 1.4% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 0.6% |
| Q4 25 | — | 1.10× | ||
| Q3 25 | — | 0.08× | ||
| Q2 25 | — | 1.75× | ||
| Q1 25 | — | 1.10× | ||
| Q4 24 | — | 1.60× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.46× | ||
| Q1 24 | — | 0.90× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CBLL
| Products | $18.8M | 76% |
| Subscription | $6.0M | 24% |
ELMD
Segment breakdown not available.
